Lisa Piazza

Dr. Lisa Piazza

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
MSMiriana Di Stefano
Miriana Di Stefano
SGSalvatore Galati
Salvatore Galati
LPLisa Piazza
Lisa Piazza
CGCarlotta Granchi
Carlotta Granchi
SMSimone Mancini
Simone Mancini
Tiziano TuccinardiTiziano Tuccinardi
Tiziano Tuccinardi
The application of artificial intelligence and machine learning (ML) methods is becoming increasingly popular in computational toxicology and drug design; it is considered as a promising solution for assessing the safety profile of compounds, particularly in lead optimization and ADMET studies, and to meet the principles of the 3Rs, which calls for the replacement, reduction, and refinement of animal testing. In this context, we herein present the development of VenomPred 2.0 (http://www.mmvsl.it/wp/venompred2/), the new and improved version of our free of charge web tool for toxicological predictions, which now represents a powerful web-based platform for multifaceted and human-interpretable in silico toxicity profiling of chemicals. VenomPred 2.0 presents an extended set of toxicity endpoints (androgenicity, skin irritation, eye irritation, and acute oral toxicity, in addition to the already available carcinogenicity, mutagenicity, hepatotoxicity, and estrogenicity) that can be evaluated through an exhaustive consensus prediction strategy based on multiple ML models. Moreover, we also implemented a new utility based on the Shapley Additive exPlanations (SHAP) method that allows human interpretable toxicological profiling of small molecules, highlighting the features that strongly contribute to the toxicological predictions in order to derive structural toxicophores.

5 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LPLisa Piazza
Lisa Piazza
MSMiriana Di Stefano
Miriana Di Stefano
CPClarissa Poles
Clarissa Poles
Giulia BononiGiulia Bononi
Giulia Bononi
Giulio PoliGiulio Poli
Giulio Poli
Tiziano TuccinardiTiziano Tuccinardi
Tiziano Tuccinardi
Background/Objectives: Human carbonic anhydrases (hCAs) are metalloenzymes involved in essential physiological processes, and their selective inhibition holds therapeutic potential across a wide range of disorders. However, the high degree of structural similarity among isoforms poses a significant challenge for the design of selective inhibitors. In this work, we present a machine learning (ML)-based platform for the isoform-specific prediction and profiling of small molecules targeting hCA I, II, IX, and XII. Methods: By integrating four molecular representations with four ML algorithms, we built 64 classification models, each extensively optimized and validated. The best-performing models for each isoform were applied in a virtual screening campaign for ~2 million compounds. Results: Following a multi-step refinement process, 12 candidates were identified, purchased, and experimentally tested. Several compounds showed potent inhibitory activity in the nanomolar to submicromolar range, with selectivity profiles across the isoforms. To gain mechanistic insights, SHAP-based feature importance analysis and molecular docking supported by molecular dynamics simulations were employed, highlighting the structural determinants of the predicted activity. Conclusions: This study demonstrates the effectiveness of integrating ML, cheminformatics, and experimental validation to accelerate the discovery of selective carbonic anhydrase inhibitors and provides a generalizable framework for activity profiling across enzyme isoforms.

13 October 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
LPLisa Piazza
Lisa Piazza
CPClarissa Poles
Clarissa Poles
Giulia BononiGiulia Bononi
Giulia Bononi
CGCarlotta Granchi
Carlotta Granchi
MSMiriana Di Stefano
Miriana Di Stefano
Tiziano TuccinardiTiziano Tuccinardi
Tiziano Tuccinardi

Verified
Journal Article
Open access
PDF file
MSMiriana Di Stefano
Miriana Di Stefano
LPLisa Piazza
Lisa Piazza
CPClarissa Poles
Clarissa Poles
SGSalvatore Galati
Salvatore Galati
CGCarlotta Granchi
Carlotta Granchi
Tiziano TuccinardiTiziano Tuccinardi
Tiziano Tuccinardi
Protein kinases are key regulators of cellular processes and critical therapeutic targets in diseases like cancer, making them a focal point for drug discovery efforts. In this context, we developed KinasePred, a robust computational workflow that combines machine learning and explainable artificial intelligence to predict the kinase activity of small molecules while providing detailed insights into the structural features driving ligand-target interactions. Our kinase-family predictive tool demonstrated significant performance, validated through virtual screening, where it successfully identified six kinase inhibitors. Target-focused operational models were subsequently developed to refine target-specific predictions, enabling the identification of molecular determinants of kinase selectivity. This integrated framework not only accelerates the screening and identification of kinase-targeting compounds but also supports broader applications in target identification, polypharmacology studies, and off-target effect analysis, providing a versatile tool for streamlining the drug discovery process.

Verified
Journal Article
Open access
PDF file
Giulia BononiGiulia Bononi
Giulia Bononi
ELEva Landucci
Eva Landucci
MSMiriana Di Stefano
Miriana Di Stefano
LPLisa Piazza
Lisa Piazza
SBSimone Bertini
Simone Bertini
CGCarlotta Granchi
Carlotta Granchi
Monoacylglycerol lipase (MAGL) is a key serine hydrolase involved in lipid metabolism, catalyzing the hydrolysis of monoacylglycerols into free fatty acids and glycerol. MAGL plays a central role in regulating endocannabinoid signaling and lipid homeostasis, processes often dysregulated in cancer and other pathological conditions. In recent years, MAGL has emerged as a promising therapeutic target, particularly in oncology, where its inhibition has shown potential to impair tumor growth, metastasis, and inflammation-driven processes. Alongside the development of selective MAGL inhibitors, several biochemical methods have been established to measure MAGL enzymatic activity, providing essential tools for target validation and inhibitor characterization. In this review, we provide a comprehensive and critical overview of the main approaches developed for MAGL activity evaluation, including radiometric, chromatographic, colorimetric, fluorescence-based, bioluminescence-based, and activity-based protein profiling (ABPP) assays. For each method, we discuss principles, advantages, and limitations. This review aims to support researchers in the selection of the most appropriate assay strategy for their experimental needs, ultimately fostering the rapid and accurate development of novel MAGL inhibitors with potential applications in cancer therapy and metabolic disease management.

20 December 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
LPLisa Piazza
Lisa Piazza
CPClarissa Poles
Clarissa Poles
Giulia BononiGiulia Bononi
Giulia Bononi
CGCarlotta Granchi
Carlotta Granchi
MSMiriana Di Stefano
Miriana Di Stefano
Luigi AlfanoLuigi Alfano
Luigi Alfano
Cyclin-dependent kinase 9 (CDK9) is a key regulator of transcriptional elongation and DNA repair, supporting cancer cell survival by sustaining the expression of oncogenes and anti-apoptotic proteins. Its overexpression in multiple malignancies makes it an attractive target for anticancer therapy. Here, we report a machine learning (ML) based approach to identify novel CDK9 inhibitors. Through systematic data collection and preprocessing, seventy predictive models were developed using five algorithms, two classification settings, and seven molecular representations. The best-performing model was employed to guide a virtual screening (VS) campaign, resulting in the identification of 14 compounds promising for their potential inhibitory effect. Upon enzymatic assays, two molecules with inhibitory activity in the low micromolar range were selected as promising candidates and further tested in three cancer cell lines with distinct genetic backgrounds. These experiments led to the identification of a novel compound exhibiting interesting therapeutic potential, both as a single agent and in combination with Camptothecin (CPT), revealing varying response profiles across the tested cell lines. These results illustrate the power of integrating ML within anticancer drug discovery pipelines and represent a valuable starting point for the development of novel CDK9 inhibitors.